NCT01276535

Study of the Use of Low Level Laser Therapy to Reduce Acne

A Pilot Study to Evaluate the Efficacy of Low-level Laser Therapy in Reducing Blemishes by Quantifying a Decrease in Signs of Blemishes, Both Non-inflammatory and Inflammatory

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Erchonia Corporation · Industry
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine whether low level laser light therapy is effective in the treatment of acne blemishes.

Detailed description

Acne is a chronic inflammatory disorder plaguing the sebaceous follicle, and debate still remains over what truly initiates lesion formation. Experts agree that an increase in androgen production plays a significant role in the onset of acne. Androgens promote the increase in size of sebaceous glands and stimulate sebum production. The simple act of sebaceous gland stimulation via androgens could ultimately promote the upregulation of pro-inflammatory cytokines like tumor necrosis factor-α (TNF-α) and interleukin (IL-1α) without propionibacteria even being present. The synthesis of IL-α and other pro-inflammatory cytokines including prostaglandins occurs via the inducible enzyme known as cyclooxygenase-2 (COX-2). Studies analyzing the pathogenesis of mucositis have identified COX-2 as an important contributor to the upregulation of pro-inflammatory cytokines and thus a major contributor to the progression of the disorder itself. Recent evidence indicates that low-level laser therapy (LLLT) is able to significantly diminish the expression of COX-2, resulting in the reduction of inflammation. The ability to modulate the COX-2 pathways via LLLT is believed to inhibit the production of pro-inflammatory cytokines (i.e. TNF-α and IL- α) present in acne-prone skin.

Conditions

• Acne

Interventions

Type	Name	Description
DEVICE	Erchonia MLS + Erchonia THL	The Erchonia® MLS is administered weekly for 6 continuous weeks at the test site by the study investigator. The Erchonia THL is administered twice daily for 6 continuous weeks (42 days) at home by the subject. Administration of the MLS and the THL occur simultaneously over the 6-week administration phase. The intent is to evaluate the effectiveness of Erchonia MLS \& Erchonia THL when administered together, and not to compare Erchonia MLS vs. Erchonia THL

Timeline

• Start date: 2010-03-01
• Primary completion: 2010-06-01
• Completion: 2010-06-01
• First posted: 2011-01-13
• Last updated: 2015-12-11
• Results posted: 2015-12-11

Locations

1 site across 1 country: United States